The purpose of this study is to compare pain associated with injections and injection-site
reactions of the approved formulation of Glatiramer Acetate (GA) versus investigational
formulation of GA. In addition, the investigators will evaluate the side effects of the two
formulations of GA.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries